Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension

被引：0
|
作者：
Reinisch, W. [1 ,2 ,3 ,4 ]
Gibson, P. [5 ]
Sandborn, W. J. [6 ]
Feagan, B. [7 ]
Marano, C. [8 ]
Strauss, R. [8 ]
Johanns, J. [8 ]
Zhang, H. [8 ]
Padgett, L. [8 ]
Adedokun, O. J. [8 ]
Colombel, J. -F. [9 ]
Collins, J. [10 ]
Rutgeerts, P. [11 ]
Tarabar, D. [12 ]
机构：
[1] Univ Klin Innere Med III, Vienna, Austria
[2] McMaster Univ, Vienna, Austria
[3] Univ Klin Innere Med III, Hamilton, Austria
[4] McMaster Univ, Hamilton, Austria
[5] Alfred Hosp, Melbourne, Vic, Australia
[6] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA 92093 USA
[7] Univ Western Ontario, Robarts Res Inst, Robarts Clin Trials Inc, London, ON, Canada
[8] Janssen R&D LLC, Spring House, PA USA
[9] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[10] Oregon Hlth & Sci Univ, Dept Gastroenterol, Portland, OR USA
[11] Univ Hosp Gasthuisberg, Dept Haematol, Leuven, Netherlands
[12] Mil Med Acad, Dept Gastroenterol & Hepatol, Belgrade 11002, Serbia
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P307
引用
收藏
页码：S248 / S249
页数：2
相关论文
共 50 条
  • [31] Population Pharmacokinetic Modeling Analysis of Golimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Liao, Sam
    Marano, Colleen
    Strauss, Rick
    Zhang, Hongyan
    Johanns, Jewel
    Davis, Hugh M.
    Reinisch, Walter
    Feagan, Brian G.
    Sandborn, William
    GASTROENTEROLOGY, 2016, 150 (04) : S408 - S408
  • [32] Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis
    Xu, Yan
    Adedokun, Omoniyi J.
    Chan, Daphne
    Hu, Chuanpu
    Xu, Zhenhua
    Strauss, Richard S.
    Hyams, Jeffrey S.
    Turner, Dan
    Zhou, Honghui
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04): : 590 - 604
  • [33] Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions
    Shao, Jie
    Vetter, Marion
    Vermeulen, An
    Feagan, Brian G.
    Sands, Bruce E.
    Panes, Julian
    Xu, Zhenhua
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (06) : 1418 - 1427
  • [34] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Abreu, Maria T.
    Danese, Silvio
    Wolf, Douglas C.
    Canavan, James B.
    Jain, Anjali
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Afzali, Anita
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S208 - S208
  • [35] Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
    Sandborn, William J.
    Feagan, Brian G.
    Hanauer, Stephen
    Vermeire, Severine
    Ghosh, Subrata
    Liu, Wenzhong J.
    Petersen, AnnKatrin
    Charles, Lorna
    Huang, Vivian
    Usiskin, Keith
    Wolf, Douglas C.
    D'Haens, Geert
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (07): : 1120 - 1129
  • [36] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
    Panaccione, R.
    Danese, S.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Afzali, A.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534
  • [37] Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis
    O'Connell, Jim
    Rowan, Cathy
    Stack, Roisin
    Harkin, Grace
    Parihar, Vikrant
    Chan, Grace
    Breslin, Niall
    Cullen, Garret
    Dunne, Cara
    Egan, Laurence
    Harewood, Gavin
    Leyden, Jan
    MacCarthy, Finbar
    MacMathuna, Padraic
    Mahmud, Nasir
    McKiernan, Susan
    McNamara, Deirdre
    Mulcahy, Hugh
    Murray, Frank
    O'Connor, Anthony
    O'Toole, Aoibhlinn
    Patchett, Stephen
    Ryan, Barbara
    Sheridan, Juliette
    Slattery, Eoin
    Doherty, Glen
    Kevans, David
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (09) : 1019 - 1026
  • [38] Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis
    Reinisch, Walter
    Loftus Jr, Edward, V
    Schreiber, Stefan
    Rubin, David T.
    Louis, Edouard
    Hecht, Patrick M.
    Barrachina, Elena Marced
    Kalabic, Jasmina
    Vladea, Ramona
    Sharma, Dolly
    Duan, Weijiang Rachel
    Zhang, Yafei
    Panaccione, Remo
    JOURNAL OF CROHNS & COLITIS, 2025, 19 (04):
  • [39] Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
    Kobayashi, Taku
    Ito, Hiroaki
    Ashida, Toshifumi
    Yokoyama, Tadashi
    Nagahori, Masakazu
    Inaba, Tomoki
    Shikamura, Mitsuhiro
    Yamaguchi, Takayoshi
    Hori, Tetsuharu
    Pinton, Philippe
    Watanabe, Mamoru
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2021, 19 (04) : 448 - +
  • [40] Comparative Efficacy and Safety of Ozanimod vs Adalimumab and Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis
    Dubinsky, Marla C.
    Betts, Keith A.
    LaPensee, Kenneth
    Eren, Devrim
    Kim-Romo, Dawn
    Yin, Lei
    Tang, Wenxi
    Gupte-Singh, Komal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S314 - S314
12345